Physician profile
David Kraman
NPI 1386649895
$9,506.73
in general payments reported to CMS, 2019-2025
41 companies · $3,473 in 2025
The $3,473 reported for 2025 was more than what 88% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $470 · 2021: $773 · 2022: $645 · 2023: $950 · 2024: $2,393 · 2025: $3,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,692 · Consulting Fee: $3,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,691.59 |
| Consulting Fee | $3,125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $3,556.67 | 2022-2025 | |
| Astellas Pharma US INC | $1,435.10 | 2019-2025 | Xtandi, Myrbetriq |
| Dentsply Ih Ab | $1,168.90 | 2023-2025 | Lofric, Lofric |
| Sumitomo Pharma America, INC. | $810.52 | 2023-2025 | Orgovyx, Gemtesa |
| Janssen Biotech, INC. | $361.52 | 2019-2025 | Erleada |
| Abbvie INC. | $279.85 | 2019-2024 | |
| Pfizer INC. | $212.36 | 2019-2025 | |
| Neotract INC. | $153.84 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $152.42 | 2019-2025 | Adstiladrin |
| Medtronic, INC. | $145.14 | 2022-2023 | Concertotm |
| 180 Medical, INC. | $127.59 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.13 | 2019-2023 | |
| Myovant Sciences INC. | $113.45 | 2021-2022 | |
| Telix Pharmaceuticals | $85.68 | 2023-2025 | Illuccix |
| Coloplast Corp | $68.55 | 2019-2023 | Speedicath |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kraman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.